Resources for Food and Drug Administration (FDA)

Orexigen Obesity Drug Works, But Fails To Meet FDA Standards

smartabouthealth.net

Orexigen Therapeutics has reported positive results in the first late-stage trial of their experimental obesity drug Contrave, but has failed to meet FDA standards.The company has been working on this experimental obesity drug for a long time and has reported positive results, but not enough to win full FDA backing.The trial on the drug was carried out on 791 patients in total.

View the Resource

Share or bookmarklet this web page at: